Glucagon as a Hyperglycemic Hormone: Technical Pros and Cons
Abstract: Glucagon, a 29-amino acid peptide hormone, is justified as a hyperglycemic agent via hepatic glycogenolysis and gluconeogenesis. Technical pros include rapid onset (5-15 min) and FDA-approved rescue kits for severe hypoglycemia; cons involve short half-life (3-6 min) and instability requiring lyophilized storage. Market trends show a 7.2% CAGR (2024-2030) driven by diabetes and obesity indications. Brand comparisons (e.g., Eli Lilly vs. Novo Nordisk) highlight purity >98% and stability differences. Product parameters (pH 2.5-3.0, reconstitution volume 1 mg/mL) dictate logistics (cold chain, 2-8°C). Industry challenges include manufacturing complexity and regulatory compliance (GMP, USP). Selection criteria prioritize potency, endotoxin levels, and supplier certifications.